FT819 Drives B cell Compartment Remodeling of Patients with Systemic Lupus Erythematosus Without Conditioning Chemotherapy
Friday, May 15, 2026 1 min read
Key Takeaway: The article discusses FT819's impact on B cell compartment remodeling in patients with systemic lupus erythematosus. Notably, this treatment was administered without the use of conditioning chemotherapy. The findings suggest potential advancements in therapeutic approaches for this condition, although specific results or implications are not detailed.
Price reaction · baseline $1.9 (2026-05-14 close) · hit pre-market · 2 other FATE headline(s) in the window, move may be shared
day 0 close
-7.6%
day 1 · peak
-8.9%
day 3
-3.2%
Market Sentiment Analysis
Full Press Release Details
• Privacy Overview
• Strictly Necessary Cookies
• 3rd Party Cookies
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognizing you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
For more information about the data we collect please visit our Privacy Policy .
Strictly Necessary Cookies is enabled at all times so that we can save your preferences for cookie settings.
This website uses Google Analytics to collect information such as the number of visitors to the site, and the most popular pages.
Keeping this cookie enabled helps us to improve our website.